CN116472053B - Crf2受体激动剂及其在治疗中的用途 - Google Patents

Crf2受体激动剂及其在治疗中的用途

Info

Publication number
CN116472053B
CN116472053B CN202180066716.XA CN202180066716A CN116472053B CN 116472053 B CN116472053 B CN 116472053B CN 202180066716 A CN202180066716 A CN 202180066716A CN 116472053 B CN116472053 B CN 116472053B
Authority
CN
China
Prior art keywords
lys
gln
leu
gglu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180066716.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN116472053A (zh
Inventor
S·伊里亚诺
L·卢卡特斯
L·莱德因
P·鲍维格
P·扎尼科
M-L·奥责奥克斯
N·哈兰德
Z·李
R·埃尔沃特
A·艾维斯
E·比安基
A·桑托普雷特
D·罗沃思
M·特利佩皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CN116472053A publication Critical patent/CN116472053A/zh
Application granted granted Critical
Publication of CN116472053B publication Critical patent/CN116472053B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180066716.XA 2020-08-19 2021-08-18 Crf2受体激动剂及其在治疗中的用途 Active CN116472053B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19
EP20315387.9 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (2)

Publication Number Publication Date
CN116472053A CN116472053A (zh) 2023-07-21
CN116472053B true CN116472053B (zh) 2026-07-31

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066716.XA Active CN116472053B (zh) 2020-08-19 2021-08-18 Crf2受体激动剂及其在治疗中的用途

Country Status (16)

Country Link
US (1) US12679878B2 (cg-RX-API-DMAC10.html)
EP (2) EP4199946B1 (cg-RX-API-DMAC10.html)
JP (2) JP7832927B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230051583A (cg-RX-API-DMAC10.html)
CN (1) CN116472053B (cg-RX-API-DMAC10.html)
AU (1) AU2021328673A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192032A1 (cg-RX-API-DMAC10.html)
ES (1) ES2988026T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240906T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066991T2 (cg-RX-API-DMAC10.html)
IL (1) IL300464B1 (cg-RX-API-DMAC10.html)
IS (1) IS3063B (cg-RX-API-DMAC10.html)
MX (1) MX2023002087A (cg-RX-API-DMAC10.html)
PL (1) PL4199946T3 (cg-RX-API-DMAC10.html)
WO (1) WO2022038179A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202301784B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4234574A1 (en) 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
KR20260089954A (ko) 2023-11-17 2026-06-16 구브라 에이/에스 hCRHR2 선택적 폴리펩타이드
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體2(crfr2)促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026139062A1 (zh) * 2024-12-26 2026-07-02 杭州先为达生物科技股份有限公司 促肾上腺皮质激素释放因子2受体激动剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013803A1 (en) * 2016-07-15 2018-01-18 Eli Lilly And Company Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013803A1 (en) * 2016-07-15 2018-01-18 Eli Lilly And Company Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
ZA202301784B (en) 2024-01-31
JP2023541798A (ja) 2023-10-04
MX2023002087A (es) 2023-03-23
EP4435001A3 (en) 2024-10-09
IL300464A (en) 2023-04-01
HRP20240906T1 (hr) 2024-10-11
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
CA3192032A1 (en) 2022-02-24
WO2022038179A1 (en) 2022-02-24
JP2026071260A (ja) 2026-04-28
JP7832927B2 (ja) 2026-03-18
PL4199946T3 (pl) 2024-08-19
HUE066991T2 (hu) 2024-09-28
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
CN116472053A (zh) 2023-07-21
IL300464B1 (en) 2026-07-01
EP4199946B1 (en) 2024-06-05
ES2988026T3 (es) 2024-11-19
US12679878B2 (en) 2026-07-14
EP4199946A1 (en) 2023-06-28
KR20230051583A (ko) 2023-04-18
AU2021328673A1 (en) 2023-03-30

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant